Advertisement

Topics

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

2014-09-18 14:20:45 | BioPortfolio

Published on BioPortfolio: 2014-09-18T14:20:45-0400

Clinical Trials [2750 Associated Clinical Trials listed on BioPortfolio]

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

The study is a randomized Phase I/II trial aiming to evaluate the 6 month treatment tolerance defined as the related grade 3-4 toxicity event-free survival and clinical activity of the com...

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab is more effective than nivolumab or ipilimumab alone in treatmen...

PubMed Articles [1310 Associated PubMed Articles listed on BioPortfolio]

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?

The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have dramatically improved outcomes for patients with metastatic melanoma; however, not all patients benefit from monotherapy ...

Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis).

Ipilimumab is a human monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen (CTLA-4) approved for treatment of metastatic melanoma. The most commonly reported side effects are imm...

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma ...

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Background Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib ...

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

Purpose Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with ...

Medical and Biotech [MESH] Definitions

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

Inhibitor or Reverse Transcriptases or of RNA-dIrected DNA polymerase.

Therapy with two or more separate preparations given for a combined effect.

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

A pharmaceutical preparation of amlodipine and valsartan that is used for the treatment of HYPERTENSION.

More From BioPortfolio on "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial